EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update
Inserm · Sorbonne Université · +44 more institutions
Abstract
New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA.
Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of evidence and grades of recommendations were determined.
Citation impact
- FWCI
- 126.73
- Percentile
- 100%
- References
- 99
Authors
36- LGLaure GossecCorresponding
Inserm, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Pitié-Salpêtrière Hospital, Institut Pierre Louis d‘Épidémiologie et de Santé Publique
- AKAndreas Kerschbaumer
Medical University of Vienna
- RJRicardo J O Ferreira
Hospitais da Universidade de Coimbra, Lisbon School of Design, Nursing Research, Innovation and Development Centre of Lisbon
- DADaniel Aletaha
Medical University of Vienna
- XBXenofon Baraliakos
Rheumazentrum Ruhrgebiet, Ruhr University Bochum
Topics & keywords
- Medicine
- Psoriatic arthritis
- Arthritis
- Intensive care medicine
- Alternative medicine
- Dermatology
- Psoriasis
- Internal medicine
- Good health and well-being